Multiple sclerosis treatment has changed considerably in recent years. For people with highly active or progressive MS, treatment is no longer limited to simply controlling symptoms or waiting for repeated relapses before using stronger therapy.
Advanced MS treatment may now include:
- High-efficacy disease-modifying therapies
- B-cell-targeted treatments
- Immune-reconstitution therapies
- Autologous haematopoietic stem cell transplantation (AHSCT)
- Newer treatments for progressive MS
- Advanced rehabilitation and symptom management
The right option depends on whether MS is relapsing or progressive, how active it is on MRI, previous treatments, disability and the patient's overall health.
For a broader introduction to diagnosis and standard therapies, see our main guide to Multiple Sclerosis (MS) Treatment.
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
What Is Considered an Advanced MS Treatment?
Advanced treatment generally refers to therapies used to achieve stronger control of MS or manage disease that remains active despite earlier treatment.
| Advanced Treatment | When It May Be Considered |
|---|---|
| High-efficacy DMT | Active or aggressive relapsing MS |
| Anti-CD20 therapy | Relapsing MS and selected primary progressive MS |
| Immune-reconstitution treatment | Selected patients needing strong long-term disease control |
| AHSCT | Highly active inflammatory MS despite high-efficacy treatment |
| Newer progressive-MS therapies | Selected forms of secondary progressive MS |
| Experimental cellular therapies | Clinical trials only |
1. High-Efficacy Disease-Modifying Therapies
Disease-modifying therapies (DMTs) aim to reduce MS relapses, inflammatory MRI activity and future disability. Traditionally, many patients began with moderately effective medicines and moved to stronger treatment only if the disease continued to be active.
Current MS practice increasingly considers high-efficacy treatment earlier, particularly when a patient already has signs of aggressive disease. High-efficacy options may include:
- Ocrelizumab
- Ofatumumab
- Natalizumab
- Alemtuzumab
- Cladribine
2. B-Cell-Targeted Treatment
B cells are immune cells that play an important role in MS inflammation. Several advanced MS therapies now specifically target these cells.
Ocrelizumab
Ocrelizumab is an anti-CD20 monoclonal antibody used for active relapsing forms of MS and for selected adults with early primary progressive MS. It reduces B-cell activity and can decrease relapses and inflammatory disease activity. Its role in primary progressive MS is particularly important because treatment options for this form of the disease have historically been limited.
Ofatumumab
Ofatumumab also targets CD20-positive B cells and is used for relapsing forms of MS. Unlike infusion-based ocrelizumab, it is administered as a subcutaneous injection according to a scheduled treatment plan.
3. Immune-Reconstitution Therapies
Some treatments are designed to produce a strong but time-limited effect on the immune system rather than requiring continuous regular therapy. Examples include:
- Cladribine
- Alemtuzumab
This approach is sometimes described as immune reconstitution.
The aim is to substantially change the immune cells responsible for MS activity and provide disease control that may continue beyond the dosing period. These treatments are powerful and require careful selection because significant infections, blood abnormalities or autoimmune complications can occur depending on the medicine.
4. Autologous Haematopoietic Stem Cell Transplantation (AHSCT)
AHSCT is one of the most intensive advanced treatments currently used for selected people with MS. It is particularly considered for highly active relapsing-remitting MS that continues to show inflammatory activity despite high-efficacy disease-modifying treatment.
AHSCT involves:
- Collecting the patient's own blood-forming stem cells
- Using chemotherapy to strongly suppress the existing immune system
- Returning the stored stem cells so the immune system can rebuild
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
Who Is Most Likely to Benefit From AHSCT?
Current ECTRIMS and EBMT recommendations suggest that the strongest evidence is in people with:
- Relapsing-remitting MS
- Highly active inflammatory disease
- Continued relapses or MRI activity despite high-efficacy DMT
- Relatively short disease duration
- Lower levels of established disability
- Good general health to tolerate transplantation
5. Advanced Treatment for Primary Progressive MS
Primary progressive MS (PPMS) causes gradual neurological worsening from the beginning rather than repeated clear relapses. Ocrelizumab is an established disease-modifying option for selected adults with early PPMS and features of inflammatory activity. However, advanced treatment for progressive MS also depends heavily on:
- Physiotherapy
- Mobility rehabilitation
- Spasticity treatment
- Pain management
- Bladder and bowel management
- Assistive technology
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
6. A Newer Treatment for Secondary Progressive MS: Tolebrutinib
Progressive MS is an area where treatment options are continuing to change. Tolebrutinib is a Bruton's tyrosine kinase (BTK) inhibitor designed to affect immune activity involving B cells and other immune cells, including mechanisms relevant within the central nervous system.
In June 2026, the European Union authorised tolebrutinib, under the brand name Cenrifki, for adults with secondary progressive MS who have had no relapses during the previous two years.
This is important because non-relapsing secondary progressive MS has historically had very limited disease-modifying treatment options. However, availability differs between countries. Tolebrutinib also requires liver-function monitoring because liver injury is an identified treatment risk.
What About CAR-T Therapy for Multiple Sclerosis?
CAR-T cell therapy is being investigated as a possible future treatment for difficult autoimmune neurological diseases, including MS. The treatment modifies a patient's immune cells so they can target particular B-cell populations. Early research is exploring whether this could produce a deeper immune reset in people with severe or treatment-resistant disease.
However: CAR-T therapy is still experimental for multiple sclerosis and is not a routine approved MS treatment. It should currently be considered only within appropriately regulated clinical research.
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
When Should Advanced Treatment Be Discussed?
A specialist may reconsider the treatment strategy when:
- Relapses continue despite treatment
- New MRI lesions continue to appear
- Disability is accumulating quickly
- The disease is highly active from the beginning
- A current DMT is not tolerated
- Progressive MS continues to worsen
The Bottom Line
Advanced treatment for multiple sclerosis is increasingly focused on controlling the disease earlier and more effectively rather than simply responding to repeated relapses. High-efficacy disease-modifying therapies such as anti-CD20 treatments, natalizumab and immune-reconstitution therapies can provide strong disease control for appropriately selected patients.
AHSCT is a more intensive option for highly active inflammatory MS that remains uncontrolled despite high-efficacy treatment. Its role is primarily to reset immune activity—not to regenerate damaged nerves. Progressive MS treatment is also evolving. Ocrelizumab remains an important option for selected primary progressive MS, while tolebrutinib became an EU-authorised treatment in 2026 for adults with secondary progressive MS without relapses during the previous two years.
Other approaches such as CAR-T cells and remyelination therapies remain under investigation. The most advanced MS treatment is therefore not necessarily the newest treatment. It is the treatment strategy that matches the type and activity of MS early enough to prevent as much irreversible neurological damage as possible.
